2020
Single-Incision 4-Compartment Fasciotomy of the Lower Leg: Safe, Effective, and Advantageous.
Chang G, Fram B, Krieg JC. Single-Incision 4-Compartment Fasciotomy of the Lower Leg: Safe, Effective, and Advantageous. Orthopedics 2020, 43: e225-e230. PMID: 32271928, DOI: 10.3928/01477447-20200404-03.Peer-Reviewed Original ResearchConceptsAcute compartment syndromeSingle-incision techniqueSkin closureInstances of malunionIntraoperative neurovascular injuryTibial fracture nonunionSingle-incision approachOptimal surgical approachMajority of surgeonsCompartment syndromeComplication rateWound breakdownSingle surgeonNeurovascular injuryRetrospective studySuperficial infectionSurgical approachFracture nonunionPrimary closureSecondary intentionSingle incisionVertical mattress suturesLower LegPatientsFasciotomy
2014
Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET
Lukens JN, Nasta SD, Fram B, Glatstein E, Plastaras JP. Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET. American Journal Of Clinical Oncology 2014, 37: 35-40. PMID: 22992623, DOI: 10.1097/coc.0b013e31826106c9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm GradingNeoplasm StagingPositron-Emission TomographyRadiotherapy, Computer-AssistedRetrospective StudiesRituximabTomography, X-Ray ComputedTreatment OutcomeConceptsInvolved field radiation therapyProgression-free survivalNon-Hodgkin lymphomaLow-grade non-Hodgkin lymphomaPositron emission tomographyIndolent non-Hodgkin lymphomaComputed tomographyWeekly dosesRadiation therapyFavorable progression-free survivalImproved progression-free survivalOverall progression-free survivalReceipt of rituximabRituximab-treated patientsUse of rituximabPFS ratesMore patientsProspective studyHistorical controlsRetrospective analysisRituximabPatientsStage IIEmission tomographySignificant differences